+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 19Years +
All Genders
ID07895394

Evaluating Immune Responses and Safety of the RSVPreF3 Vaccine in Lung Transplant Recipients and Older Adults

Led by Seoul National University Hospital · Updated on 2026-10-26

80

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the immune response and safety of a respiratory syncytial virus RSV vaccine in lung transplant recipients compared to immunocompetent adults. The study aims to provide evidence to guide RSV vaccination in lung transplant recipients, who are at higher risk due to immunosuppressive therapy. This Phase 4 trial focuses on prevention and involves adults aged 19 years and older. Participants will receive a single intramuscular dose of the RSVPreF3 vaccine Arexvy. The study includes two groups lung transplant recipients aged 19 and older who are on immunosuppressive therapy, and immunocompetent adults aged 60 and older without immune-compromising conditions. Immune responses will be measured before vaccination, and at 1 month and 12 months after vaccination, with safety monitored throughout. During the study, participants will be contacted by phone 7 days after vaccination and will have a follow-up visit at 30 days to assess any adverse events. Immunogenicity assessments will include measurement of neutralizing antibodies and cell-mediated immunity. Safety evaluations will continue for up to 12 months after vaccination. The total participation period extends to about one year after vaccination.

CONDITIONS

Brief Title

Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients

Research Team

C

Chan Mi Lee, M.D., PhD.

Y

Young Hoon Hwang, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here